Return to homepagePandemic Pact

PlasmACoV2

  • Funded by Etablissement Français du Sang
  • Total publications:0 publications

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    Etablissement Français du Sang

  • Principal Investigator

    N/A

  • Research Location

    France

  • Lead Research Institution

    N/A

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Immunity

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Unspecified

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

The EFS began on Tuesday, April 7, collecting plasma from convalescents, i.e. donors who have had COVID19, as part of a study called PlasmACoV2. This study will in particular characterize the products by performing the titration of the neutralizing, anti-SARS-CoV-2 antibodies and by evaluating the inflammatory potential of the plasma. Based on the results of this study, products were selected to assess their effectiveness against the disease in hospitalized patients with COVID19. This test, piloted by the APHP is entitled CORIPLASM.